Foravirumab

Foravirumab is an experimental monoclonal antibody designed for the treatment of HIV infection. It was developed by Progenics Pharmaceuticals and is currently in the preclinical stage of development.

Mechanism of Action

Foravirumab works by binding to the gp120 protein on the surface of the HIV virus. This prevents the virus from attaching to and entering human cells, thereby stopping the spread of the infection.

Development and Clinical Trials

Foravirumab is currently in the preclinical stage of development. This means that it has not yet been tested in humans. The safety and efficacy of foravirumab are currently being evaluated in laboratory and animal studies.

Potential Advantages

Foravirumab has the potential to offer several advantages over existing HIV treatments. It is a monoclonal antibody, which means it is highly specific for its target and is less likely to cause side effects. Additionally, foravirumab could potentially be used in combination with other HIV treatments to increase their effectiveness.

Potential Disadvantages

As foravirumab is still in the preclinical stage of development, its potential disadvantages are not yet known. However, like all drugs, it may have side effects and may not work for everyone.

See Also

• Monoclonal antibodies
• HIV/AIDS
• Progenics Pharmaceuticals
• Clinical trial
• gp120